R&D spending share of top pharmaceutical companies 2018 and 2024

In 2018, pharmaceutical companies AstraZeneca and Eli Lilly each spent about a quarter of their prescription drug revenue on research and development. The companies are predicted to spend roughly two percent less of their revenue share on R&D in 2024.

Global R&D spending

In 2018, the pharmaceutical industry spent just under 180 billion U.S. dollars on research and development, which is an increase of over 10 billion compared to the previous year. By 2024, expenditures are expected to reach a total of over 210 billion U.S. dollars. Some 15 thousand prescription drugs were in the 2018 R&D pipeline, a global number that has been growing with each consecutive year. The drug count has doubled since 2006 and is set to increase even further in the future.

AstraZeneca

AstraZeneca is a British-Swedish multinational pharmaceutical company, based in Cambridge, United Kingdom. The company’s top product in 2018 was Symbicort, which is used for controlling and preventing symptoms of asthma. The product generated close to 2.6 billion U.S. dollars in revenue that year. Revenue earned through Symbicort has decreased each year since 2015.

Top 10 pharmaceutical companies based on R&D spending as revenue share in 2018 and 2024*

Exclusive Premium statistic

You need a Single Account for unlimited access.

  • Full access to 1m statistics

  • Incl. source references

  • Available to download in PNG, PDF, XLS format

Single Account

$39 $59 per month *
in the first 12 months
33% Discount until June 30th
*Duration: 12 months, billed annually, single license

Access to this and all other statistics on 80,000 topics from

$468 / Year
$708 / Year

Show detailed source information?
Register for free
Already a member?
Log in
Source

Release date

June 2019

Region

Worldwide

Survey time period

as of May 2019

Supplementary notes

* R&D spending as a share of total prescription revenue. The statistic includes only the companies with the highest amount of R&D spending dollars.
** Forecast.

Statista Accounts: Access All Statistics. Starting from $468 / Year
Basic Account
Get to know the platform

You only have access to basic statistics.
This statistic is not included in your account.

Single Account
Your perfect start with Statista
  • Instant access to 1m statistics
  • Download in XLS, PDF & PNG format
  • Detailed references
$59 $39 / Month *
in the first 12 months
Corporate Account
Full access

Corporate solution including all features.

* All products require an annual contract; Prices do not include sales tax.

Statistics on "Pharmaceutical research and development"

Statista Accounts: Access All Statistics. Starting from $468 / Year
Learn more about how Statista can support your business.